ERBB2 and breast carcinoma: Trastuzumab (Herceptin®, Genentech Corporation, United States/Hoffman-Roche, Switzerland), a monoclonal IgG1 class humanized murine antibody, binding the ECD of HER2 transmembrane receptor.75 It was first approved for breast cancer treatment directed against HER2.76